Program
Day 1 “Tumor immunology & immunotherapy”
09.00 – Registration – Poster installation
09.30 – Opening 10min
SESSION 01:
09.40 – Keynote lecture – Bart Lambrecht
Alveolar macrophage-fibroblast crosstalk in the metastatic niche
10.20 – Jérôme Galon
10.45 – Coffee break
11.15 – Rémy Nicolle
A multimodal insight into the microenvironment of pancreatic cancer
11.40 – Julie Helft
Macrophages and antitumor immunity
12.05 – Elodie Segura
Impact of nutrition on responses to anti-PD1 therapy
12.30 – Lunch break – Poster Session – Visit to sponsors
14.00 – Partners symposia – Tecan
SESSION 02:
14.30 – Keynote lecture – Bana Jabri
15.10 – Chrysothemis Brown
Tolerogenic antigen-presenting cells: coming of age
15.35 – Ignacio Melero
Translating CD137 (4-1BB) agonist agents in combination immunotherapies
16.00 – Ivo Gomperts Boneca
An exopolysaccharide as a Trojan horse for immune modulation of the host response
16.25 – 3 selected abstracts:
– Pauline HAMON : TREM2 macrophages are associated with enhanced response to PD-1 blockade in hepatocellular carcinoma
– Salad MOHAMMADNEZHADDARYANI : Targeting eIF4F-depedent mRNA translation to mitigate T cell exhaustion and enhance PD-1 blockade efficacy in melanoma
– Olivia GHIRARDELLI SMITH :CD8 T cells can instruct the innate immune system to eradicate tumors
17.10 – Coffee break
17.40 – Janne Lehtiö
Cancer Proteogenomics- Bridging the Genotype – Phenotype Gap with MolecularData
18.05 – Carsten Denkert
Modulation of tumor-microenvironment and biomarker strategies in breast cancer immunotherapy
18.30 – Guido Kroemer
A neuroendocrine factor controlling the cancer-immunity dialogue
18.55 – Seerave Foundation
19.05 – Welcome reception
20.30/21.00 – Speakers / Oncobiome / Seerave dinner
Day 2 “Microbiota-immune interface »
SESSION 03:
09.00 – Keynote lecture – Dan Littman
09.40 – Tim Greten
The Immune Tumor Microenvironment in the Liver
10.05 – Gianluca Ianiro
Targeted fecal microbiota transplantation to boost efficacy of immune checkpoint inhibitors
10.30 – Coffee break
11.00 – Francesca Gazzaniga
Overcoming microbiome dependent resistance to cancer immunotherapy
11.25 – Benoit Chassaing
Mucus-Associated Microbiota: From Symbiosis to Dysbiosis in Health and Disease
11.50 – Johannes R. Björk
Integrated microbiome-metabolomics analysis reveals associations with diet, concomitant drugs, and ICB response
12.15 – Lunch break – Poster Session – Visit to sponsors
13.45 – “Meet the Editors” Session (Cancer Discovery, Cancer Cell, Cell, Nature Cancer, Nature Medicine)
SESSION 04:
15.00 – Laurence Albiges
15.25 – Marlies Meisel
Exercise-induced microbiota metabolite enhances cancer immunotherapy efficacy
15.50 – Giorgio Trinchieri
The gut microbiome as predictor and target for cancer immunotherapy response
16.15 – 3 selected abstracts
– Francesca CORDERO : Functional Profiling of the Cancer-Associated Microbiome: A Constraint-Based Approach to Identifying Core Microbial Communities
– Cécile ALANIO : The critical role of the host endogenous compartment after intracerebroventricular CAR T cell therapy in recurrent GBM
– François GOLDWASSER : The energetic metabolism of the host predicts the 6-month progression-free and overall survival in lung cancer patients treated with anti-PD1
17.00 – Coffee break
17.30 – Jian Xu
The iMAPS Consortium: addressing microbiome single-cell 6W (What, Who, Why, Wealth, When, Where) by the Meta-ramanomics Platform
17.55 – Jean-Jacques Trochon
Cancer and metabolic interventions; The proactive role of the patient
18.20 – Bertrand Routy
Strategies to improve the microbiome composition from bench to bedside
18.45 – Laurence Zitvogel
Gut dysbiosis is a risk factor for immunoresistance in oncology and vaccines
19.10 – Closing ceremony